Table 2

CIR at 5 years after the end of induction therapy, by patient characteristics

5-year CIR (95% CI)P*
All patients 23.4 (17.1-31.8)  
Body fat category   
    Underweight/normal 11.2 (5.3-23.8) .029 
    Overweight/obese 31.6 (22.7-43.8)  
Age at diagnosis   
    ≤ 40 years 18.7 (11.2-31.3) .34 
    > 40 years 27.8 (18.9-40.8)  
Sex   
    Male 32.2 (22.2-46.7) .079 
    Female 16.4 (9.7-27.6)  
French-American-British subtype   
    Typical 22 (15.4-31.4) .16 
    Variant 30.4 (16.4-56.5)  
PML/RARα   
    BCR1-2 16.1 (9.6-27.2) .027 
    BCR3 32.6 (22.5-47.2)  
WBC   
    ≤ 10 × 109/L 24.4 (17.2-34.6) .99 
    > 10 × 109/L 20.6 (10.6-39.8)  
Platelets   
    ≤ 40 21.7 (14.7-32) .70 
    > 40 27.4 (16.4-45.5)  
Hemoglobin   
    ≤ 10 g/dL 26 (18.1-37.3) .21 
    > 10 g/dL 18.7 (10.4-33.8)  
Sanz risk score   
    Low 24.7 (13.5-45.2) .94 
    Intermediate 25.2 (16.5-38.7)  
    High 18.9 (9.7-36.9)  
Differentiation syndrome   
    No 22.8 (16.3-32.1) .98 
    Yes 26.1 (12.2-55.7)  
5-year CIR (95% CI)P*
All patients 23.4 (17.1-31.8)  
Body fat category   
    Underweight/normal 11.2 (5.3-23.8) .029 
    Overweight/obese 31.6 (22.7-43.8)  
Age at diagnosis   
    ≤ 40 years 18.7 (11.2-31.3) .34 
    > 40 years 27.8 (18.9-40.8)  
Sex   
    Male 32.2 (22.2-46.7) .079 
    Female 16.4 (9.7-27.6)  
French-American-British subtype   
    Typical 22 (15.4-31.4) .16 
    Variant 30.4 (16.4-56.5)  
PML/RARα   
    BCR1-2 16.1 (9.6-27.2) .027 
    BCR3 32.6 (22.5-47.2)  
WBC   
    ≤ 10 × 109/L 24.4 (17.2-34.6) .99 
    > 10 × 109/L 20.6 (10.6-39.8)  
Platelets   
    ≤ 40 21.7 (14.7-32) .70 
    > 40 27.4 (16.4-45.5)  
Hemoglobin   
    ≤ 10 g/dL 26 (18.1-37.3) .21 
    > 10 g/dL 18.7 (10.4-33.8)  
Sanz risk score   
    Low 24.7 (13.5-45.2) .94 
    Intermediate 25.2 (16.5-38.7)  
    High 18.9 (9.7-36.9)  
Differentiation syndrome   
    No 22.8 (16.3-32.1) .98 
    Yes 26.1 (12.2-55.7)  
*

Gray test, comparing cumulative incidences among categories.

or Create an Account

Close Modal
Close Modal